An Oregon Health & Science University team reported in Cell Reports Medicine that pairing venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity across >300 AML patient samples and in mouse xenografts. The combination co‑targets cell‑cycle and protein‑synthesis pathways and overcomes resistance mechanisms seen with venetoclax monotherapy. Lead and corresponding authors provided mechanistic data supporting the synergy and suggest the regimen mitigates common venetoclax resistance routes. The study positions palbociclib, an approved breast‑cancer drug, as a rapid repurposing candidate for AML combination trials. Investigators and sponsors will need to define dosing, myelosuppression risk and biomarker strategies before clinical translation.